Rheumatoid Arthritis
What is Rheumatoid Arthritis?
Rheumatoid arthritis (RA) is the most common systemic inflammatory rheumatic disease. It is a chronic condition in which the immune system mistakenly attacks the body’s own tissues, particularly the joints. This loss of immune tolerance leads to persistent inflammation of the synovial membrane, the tissue that lines and protects the joints, eventually causing damage to cartilage and bone.
People with RA typically experience joint pain, swelling, stiffness, and warmth, especially in the hands, wrists, and feet. Beyond the joints, RA can also affect other organs, leading to cardiovascular, lung, skin, and bone complications. If not properly treated, the disease can progress to cause significant joint destruction, deformities, chronic pain, and long-term disability.
RA is a systemic disease, meaning it can affect the whole body. Patients also face an increased risk of mortality, largely due to associated cardiovascular and respiratory diseases, as well as infections. The causes of RA are not fully understood, but the disease arises from a combination of genetic, hormonal, and environmental factors, such as smoking or certain infections. RA is two to three times more common in women, and onset most often occurs between the ages of 40 and 60.
According to recent estimates, around 17.6 million people worldwide were living with rheumatoid arthritis in 2020, and this number is expected to rise to nearly 32 million by 2050, driven mainly by population growth and ageing.
Although there is no cure for RA, advances in treatment, including immune-modulating drugs, biologic therapies, and targeted small molecules, now allow many patients to control inflammation, slow disease progression, and maintain a good quality of life. Early diagnosis and consistent management are key to preventing irreversible joint damage and improving long-term outcomes.
Difficult-to-Treat RA: Understanding an Emerging Clinical Challenge
Difficult-to-Treat Rheumatoid Arthritis (D2T-RA) refers to cases of rheumatoid arthritis in which the disease remains active despite several types of treatment. Most people improve with modern medicines that control inflammation, but around 5–20% of patients continue to have symptoms even after trying multiple therapies.
D2T-RA happens for many reasons. In some people, the immune system follows alternative pathways that current drugs do not fully block. Long-lasting inflammation may also cause permanent changes inside the joints, making them harder to calm down. Other health conditions, side effects, or medication resistance can contribute too. In some cases, even when inflammation decreases, the nervous system keeps sending pain signals, making the disease feel uncontrolled.
Living with D2T-RA can be challenging, but regular medical follow-up, physical therapy, emotional support, and healthy lifestyle habits can help manage symptoms and maintain quality of life. Researchers are working to understand the biological mechanisms behind treatment resistance and to develop more precise, personalized therapies. The goal is that in the future, every person with rheumatoid arthritis — even those with difficult-to-treat disease — can achieve lasting relief and a better quality of life.
.
Funded by the European Union (grant agreement no. 101080243). Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.
The project has also received funding from the Swiss State Secretariat for Education, Research and Innovation (SERI) and from Hungary’s National Research, Development and Innovation (NRDI) Fund.